Correlation between in vivo and in vitro hepatic uptake of metabolic inhibitors of cytochrome P-450 in rats

Drug Metabolism and Disposition

Volumn 27, Issue 11, 1999, Pages 1225-1231

  Yamano, Katsuhiro ^a,b   Yamamoto, Koujirou ^c   Kotaki, Hajime ^d   Takedomi, Sayuri ^e   Matsuo, Hirotami ^e   Sawada, Yasufumi ^e   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CIPROFLOXACIN; CLARITHROMYCIN; CYTOCHROME P450 INHIBITOR; DILTIAZEM; ENOXACIN; ITRACONAZOLE; KETOCONAZOLE; NIZATIDINE; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONCENTRATION RESPONSE; CORRELATION FUNCTION; DRUG ACCUMULATION; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL; LIVER METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 0032755435     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Adams RM, Wang M, Crane AM, Brown B, Darlington GJ and Ledley FD (1995) Effective cryopreservation and long-term storange of primary human hepatocytes with recovery of viability, differentiation, and replicative potential. Cell Transplant 4:579-586.
2. Ahonen J, Olkkola KT and Neuvonen PJ (1995) Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol 40:270-272.
3. Backman JT, Aranko K, Himberg JJ and Olkkola KT (1994) A pharmacokinetic interaction between roxithromycin and midazolam. Eur J Clin Pharmacol 46:551-555.
4. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 25:261-270.
5. Baur H, Kasperek S and Pfaff E (1975) Criteria of viability of isolated liver cells. Hoppe-Seyler's Z Physiol Chem 356:827-838.
6. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
7. Davis JD, Aarons L and Houston JB (1995) Effect of norfloxacin on theophylline disposition: A comparison with other fluoroquinolones. Pharm Res 12:257-262.
8. Fee JPH, Collier PS, Howard PJ and Dundee JW (1987) Cimetidine and ranitidine increase midazolam bioavailability. Clin Pharmacol Ther 41:80-84.
9. Fischer U, Rohde B, Wacke R, Stange J, Nitschke FP, Adam U and Drewelow B (1997) Prediction of in vivo drug interaction from in vitro systems exemplified by interaction between verapamil and cimetidine using human liver microsomes and primary hepatocytes. J Clin Pharmacol 37:1150-1159.
10. Fujieda Y, Yamaoka K, Ito T and Nakagawa T (1996) Local absorption kinetics of levofloxacin from intestinal tract into portal vein in conscious rat using portal-venous in concentration difference. Pharm Res 13:1201-1204.
11. Gascon MP and Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41:573-578.
12. Ghosal A, Satoh H, Thomas PE, Bush E and Moore D (1996) Inhibition and kinetics of cytochrome P450 3A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
13. Hoffman DJ, Seifert T, Borre A and Nellans HN (1995) Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm Res 12:889-894.
14. Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D and Coassolo P (1997) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in human. Pharm Res 14:152-155.
15. Lin JH, Sugiyama Y, Awazu S and Hanano M (1982) In vitro and in vivo evaluation of the tissue-to-plasma partition coefficient for physiological pharmacokinelic models. J Pharmacokinet Biopharm 10:637-647.
16. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
17. Meijer DKF, Mol WEM, Muller M and Kurz G (1990) Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations. J Pharmacokinet Biopharm 18:35-70.
18. Miyauchi S, Sawada Y, Iga T, Hanano M and Sugiyama Y (1993) Comparison of the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat livers. Pharm Res 10:434-440.
19. Nakamura H, Sano H, Yamazaki M and Sugiyama Y (1994) Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: Contribution of type 1 system. J Pharmcol Exp Ther 269:1220-1227.
20. Olinga P, Merema M, Hof IH, Slooff MJH, Proost JH, Meijer DKF and Groothuis GMM (1998) Characterization of the uptake of rocuronium and digoxin in human hepatocytes: Carrier specificity and comparison with in vivo data. J Pharmcol Exp Ther 285:506-510.
21. Olkkola KT, Ahonen J and Neuvonen PJ (1996) The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 82:511-516.
22. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305.
23. Olkkola KT, Backman JT and Neuvonen PJ (1994) Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55:481-485.
24. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, Mcvicar JP, Barr DM, Gillies BS and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
25. Pichard L, Fahre I, Fabre G, Domergue J, Saint Aubert B, Mourad G and Maurel P (1990) Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P450 (Cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-606.
26. Sun EL, Feenstra KL, Bell FP, Sanders PE, Slatter JG and Ulrich RG (1996) Biotransformation of lifibrol (U-83860) to mixed glyceride metabolites by rat and human hepatocytes in primary culture. Drug Metab Dispos 24:221-231.
27. Tabata K, Yamaoka K, Fukuyama T and Nakagawa T (1995) Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. Pharm Res 12:880-883.
28. Takedomi S, Matsuo H, Yamano K, Yamamoto K, Iga T and Sawada Y (1998) Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats. Drug Metab Dispos 26:318-323.
29. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD and Wilkinson GR (1996) Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 59:491-502.
30. Yamano K, Yamamoto K, Kotaki H, Sawada Y and Iga T (1999) Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver. Drug Metab Dispos 27:395-402.
31. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetics analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.
32. Yamazaki M, Suzuki H and Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497-513.
33. Wrighton SA and Ring BJ (1994) Inhibition of human CYP3A catalyzed 1′-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine and nizatidine. Pharm Res 11:921-924.